Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cedazuridine Thorough QTc Study in Healthy Subjects
NCT04953923Phase 1Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cedazuridine in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) (4 arms), sponsored by Astex Pharmaceuticals. Primary endpoint: Change from baseline in QTcF at Day 20. Started Jul 2021; status: completed.
02
Drugs
cedazuridine
03
Conditions
myelodysplastic syndromes (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04953923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953923.